![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Group Plans to Stop Pfizer’s Patent on the Pneumonia Vaccine in India
Group Plans to Stop Pfizer’s Patent on the Pneumonia Vaccine in India
March 17, 2016
Doctors Without Borders has launched an effort in India to stop Pfizer from patenting its pneumococcal conjugate vaccine, Prevnar 13.
It marks the first time a medical organization launched a patent opposition in India, according to the group. The group says Pfizer has priced the vaccine out of reach in developing countries.
The group adds that a similar patent already has been revoked by the European Patent Office and is being challenged in South Korea.
Upcoming Events
-
21Oct